Dr. Deval Lashkari began serving on RareCyte's Board of Directors in 2009 and is a Partner with Telegraph Hill Partners (THP). Deval has worked in the life sciences area since 1988 developing and commercializing novel technologies. He gained corporate and business development experience through senior management positions in a number of life science companies. He was a founding Research Director at Synteni, which was acquired by Incyte Genomics, where he became Director of Product Development. He also worked with Operon Technologies (acquired by Qiagen), and Genometrix. Deval has also represented THP on the boards of AcroMetrix (acquired by Life Technologies), Althea Technologies, AltheaDx, Applied Precision (Acquired by GE), Aurora Discovery (acquired by NEXUS Biosystems), NEXUS Biosystems (acquired by Brooks Automation), and SwitchGear Genomics. He was an observer on the board of Dharmacon (acquired by Fisher Scientific). Deval received a BA from the University of California, Berkeley and a Ph.D. from Stanford University.
Dr. Caroline Popper, a bioscience executive, joined RareCyte's Board of Directors in 2009. Caroline, the president and co-founder of Popper and Company, has 17 years of hands-on biotech/life sciences operating experience. An internist and pathologist, she combines this perspective with that gained from managing a wide spectrum of life sciences businesses in diagnostics, devices and drug discovery. She has business management experience in both Fortune 500 and start-up settings and an extensive track record of creating strategic and business partnerships in the biotech arena. In a 10-year career at Becton Dickinson (NYSE: BDX), Caroline's global responsibilities included clinical affairs, marketing, strategy, and business development. She was the founding General Manager of BDGene; a start-up focused, with its partner Millennium Pharmaceuticals, on development of novel cancer diagnostics. From 2000 to 2002, she was the Chief Business Officer for MDS Proteomics, a drug discovery company with operations in the US, Canada and Europe.
Ron Seubert is the founder and CEO of RareCyte. Previously Ron was co-founder of both Applied Precision LLC and Applied Precision Inc. (API). Over a period of 20 years as President and CEO, Ron led these companies through consistent and rapid growth by developing innovative products in both the life sciences and semi-conductor industries. Most notably, API developed the DeltaVision microscopy line of products that led the way in live cell and high resolution microscopy as well as an OEM business that built technologies for companies like Becton Dickinson (NYSE: BDX). In 2011, API was sold to GE Healthcare and RareCyte was spun-out with an equity investment from Telegraph Hill Partners and management.
Bob Shepler has been a member of RareCyte's Board of Directors since 2009 and is a Managing Director at Telegraph Hill Partners (THP). He has been a corporate transactions specialist and investor since 1978, with a focus on strategic M&A transactions. He and his partner, Matt Mackowski, partnered together in 1991 to form THP's predecessor focused on investing in private healthcare companies. During his career, he has served on numerous company boards and completed over 150 M&A and financing transactions. Bob has represented THP on the boards of Agena Bioscience, Kinetikos Medical (acquired by Integra), AcroMetrix (acquired by Life Technologies), Aurora Discovery (acquired by NEXUS Biosystems), Applied Precision (acquired by GE), LDR Spine (IPO, NASDAQ: LDRH), Estech (acquired by Atricure) and VidaCare (acquired by Teleflex). Prior to joining with Mr. Mackowski, Bob worked with Merrill Lynch & Co. as an officer in their San Francisco corporate finance office, where he managed financings and acquisitions for Fortune 500 and selected high growth companies. Bob received a BA from Duke University and an MBA from New York University.
Dr. Peter Sorger is the Otto Krayer Professor of Systems Pharmacology at Harvard Medical School (HMS) and co-founder of the Open Microscopy Environment (OME), MIT's Computational and Systems Biology Initiative (CSBi), the Council for Systems Biology in Boston (CSB2; www.csb2.org) and companies that include Merrimack Pharmaceuticals and Glencoe Software . He is director of the Center for Cell Decision Processes, an NIH Center of Excellence in Systems Biology and co-directs a new HMS program in Systems Pharmacology. Peter received his A.B. from Harvard College, Ph.D. from Trinity College Cambridge, U.K. and trained as a postdoctoral fellow with Harold Varmus and Andrew Murray at the University of California, San Francisco. Peter has been a member of RareCyte's Board of Directors since 2009.
Joe Victor is currently the CEO of Startide Sciences, a 5AM Ventures portfolio company chartered to identify groundbreaking life science companies that can benefit from active capital. Joe brings more than 30 years of experience fostering product innovation and building value for customers, shareholders, and employees. Prior to Startide, he was CEO of DVS Sciences, a designer and manufacturer of a transformational bioanalytical mass cytometry platform and consumables. DVS was acquired in 2014 by Fluidigm, Inc. Before that, Joe was CEO of Applied Precision Inc., a manufacturer of high performance microscopy systems for life sciences research and drug development that was acquired by GE Healthcare in 2011.
Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington. Mr. Victor serves on several boards including Biodesy, RareCyte, Glencoe Software, and the UC Davis Ecosystem for Biophotonics Innovation.
Dr. Witney most recently served as President and Chief Executive Officer of Affymetrix, Inc. (now part of Thermo Fisher Scientific), which specialized in microarray technology and cellular analysis. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market leading ion and high performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix when it acquired Panomics Inc., a quantitative biology company, which he led as President and Chief Executive Officer. He previously held the role of President of PerkinElmer’s Drug Discovery Tools division following the acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market.
Dr. Witney was a post-doctoral fellow at the National Institutes of Health from 1980 to 1983 and holds a doctorate in molecular and cell biology from Indiana University. He earned an undergraduate degree in microbiology from the University of Illinois. Dr. Witney is currently Chairman of the Board for Gyros Protein Technologies AB and also holds Board positions for Cerus Corporation and Exagen Diagnostics.
Dr. Witney brings deep market knowledge and over 30 years of leadership experience across the life sciences, diagnostics and analytical instruments industry.Our Management Team